Results 271 to 280 of about 29,580 (292)
Some of the next articles are maybe not open access.

Ruxolitinib

Reactions Weekly, 2017
  +5 more sources

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Journal of the American Academy of Dermatology, 2021
Jacek C Szepietowski   +2 more
exaly  

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

Journal of Clinical Oncology, 2020
Stephen T Oh   +2 more
exaly  

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

Leukemia, 2020
Felicitas La Rosée   +2 more
exaly  

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Leukemia, 2021
Tiziano Barbui   +2 more
exaly  

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

New England Journal of Medicine, 2020
Robert Zeiser   +2 more
exaly  

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Cytokine and Growth Factor Reviews, 2020
Bakiye Goker Bagca, Cigir Biray Avci
exaly  

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Leukemia, 2015
Robert Zeiser   +2 more
exaly  

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Lancet Oncology, The, 2017
Francesco Passamonti   +2 more
exaly  

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Lancet Haematology,the, 2017
Claire N Harrison   +2 more
exaly  
myelofibrosis
medicine
internal medicine
bone marrow
immunology
biology
oncology
cancer research
biochemistry
previous   26  27  28  29  30  

Home - About - Disclaimer - Privacy